Download PDF
Thromb Haemost 2010; 103(03): 481-483
DOI: 10.1160/TH09-12-0828
Editorial Focus
Schattauer GmbH

Another oral thrombin inhibitor for stroke prevention in atrial fibrillation?

John W. Eikelboom
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Jeffrey I. Weitz
1   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
2   Department of Biochemistry and Biomedical Sciences and Henderson Research Centre, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received: 10 December 2009

Accepted: 10 March 2009

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Lip GY, Tse HF. Management of atrial fibrillation. Lancet 2007; 370: 604-618.
    CrossrefPubMedGoogle Scholar
  • 2 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
    CrossrefPubMedGoogle Scholar
  • 3 Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-1875.
    CrossrefPubMedGoogle Scholar
  • 4 Connolly SJ, Pogue J, Eikelboom J. et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
    CrossrefPubMedGoogle Scholar
  • 5 Testa L, Bhindi R, Agostoni P. et al. The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. Expert Opin Drug Saf 2007; 6: 397-406.
    CrossrefPubMedGoogle Scholar
  • 6 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361: 1139-1151.
    CrossrefPubMedGoogle Scholar
  • 7 Deinum J, Mattsson C, Inghardt T. et al. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thromb Haemost 2009; 101: 1051-1059.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Olsson SB, Rasmussen LH, Tveit A. et al. Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost 2010; 103: 604-612.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Lip GY, Rasmussen LH, Olsson SB. et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2009; 30: 2897-2907.
    CrossrefPubMedGoogle Scholar